Literature DB >> 22937846

Do cystic vestibular schwannomas have worse surgical outcomes? Systematic analysis of the literature.

Jai Deep Thakur1, Imad Saeed Khan, Cedric D Shorter, Ashish Sonig, Gale L Gardner, Bharat Guthikonda, Anil Nanda.   

Abstract

OBJECT: The goal of this study was to perform a systematic quantitative comparison of the surgical outcomes between cystic vestibular schwannomas (CVSs) and solid vestibular schwannomas (SVSs).
METHODS: A review of English-language literature published between 1990 and 2011 was performed using various search engines including PubMed, Google Scholar, and the Cochrane database. Only studies that reported surgical results of CVSs in comparison with SVSs were included in the analysis. The primary end point of this study was surgical outcomes, defined by the following: 1) facial nerve outcomes at latest follow-up; 2) mortality rates; or 3) non-facial nerve complication index. Secondary end points included extent of resection and brainstem adherence.
RESULTS: Nine studies comprising 428 CVSs and 1287 SVSs were included in the study. The mean age of patients undergoing surgery was 48.3 ± 6.75 and 47.1 ± 9 years for CVSs and SVSs, respectively (p = 0.8). The mean tumor diameter for CVSs was 3.9 ± 0.84 cm and that for SVSs was 3.7 ± 1.2 cm (p = 0.7). There was no significant difference in the extent of resection among CVSs and SVSs (81.2% vs 80.7%, p = 0.87) Facial nerve outcomes were significantly better in the cohort of patients with SVSs than in those with CVSs (52.1% vs 39%, p = 0.0001). The perioperative mortality rates for CVSs and SVSs were not significantly different (3% and 3.8%, respectively; p = 0.6). No significant difference was noted between the cumulative non-facial nerve complication rate (including mortality) among patients with CVSs and SVSs (24.5% and 25.6%, respectively; p = 0.75)
CONCLUSIONS: Facial nerve outcomes are worse in patients undergoing resection for CVSs than in patients undergoing resection for SVSs. There were no significant differences in the extent of resection or postoperative morbidity and mortality rates between the cohorts of patients with vestibular schwannomas.

Entities:  

Mesh:

Year:  2012        PMID: 22937846     DOI: 10.3171/2012.6.FOCUS12200

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  6 in total

1.  Efficacy of cyst-cisternal shunt for refractory cyst regrowth of cystic vestibular schwannomas.

Authors:  Ryouken Kimura; Katsuyoshi Miyashita; Sho Tamai; Yosuke Kawahara; Mitsutoshi Nakada
Journal:  Acta Neurochir (Wien)       Date:  2019-06-28       Impact factor: 2.216

Review 2.  Facial Nerve Function Outcome and Risk Factors in Resection of Large Cystic Vestibular Schwannomas.

Authors:  Daniela Stastna; Richard Mannion; Patrick Axon; David Andrew Moffat; Neil Donnelly; James R Tysome; David G Hardy; Mahonar Bance; Alexis Joannides; Indu Lawes; Robert Macfarlane
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-01

Review 3.  Microsurgical resection of vestibular schwannomas: complication avoidance.

Authors:  Shervin Rahimpour; Allan H Friedman; Takanori Fukushima; Ali R Zomorodi
Journal:  J Neurooncol       Date:  2016-09-20       Impact factor: 4.130

Review 4.  Comparison of surgical outcomes in cystic and solid vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Xiaolong Wu; Gang Song; Xu Wang; Mingchu Li; Ge Chen; Hongchuan Guo; Yuhai Bao; Jiantao Liang
Journal:  Neurosurg Rev       Date:  2020-10-02       Impact factor: 3.042

5.  Clinical comparison of two subtypes of cystic vestibular schwannoma: surgical considerations and outcomes.

Authors:  Zirong Huo; Zhihua Zhang; Qi Huang; Jun Yang; Zhaoyan Wang; Huan Jia; Hao Wu
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-16       Impact factor: 2.503

6.  Endoscope-Assisted Retrosigmoid Approach for Vestibular Schwannomas With Intracanalicular Extensions: Facial Nerve Outcomes.

Authors:  Yunke Bi; Yunjia Ni; Dandan Gao; Qingwei Zhu; Qiangyi Zhou; Junjia Tang; Juan Liu; Fei Shi; Hongchan Li; Jian Yin; Yaohua Liu; Meiqing Lou
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.